Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) Stock Price

CUVLStock

$5.24−35.55%52W

Market Cap$264.30M

P/E10.90x

PEG Ratio1.63

Div yield0.29%

Beta0.24

CUVL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-27.28%

Price vs S&P 500 (4W)-7.04%

PEG Ratio1.63

VGM Score38.28

P/E Ratio (Annual)10.90x

Indicated Dividend Yield (Annual)0.29%

P/CF (Annual)10.01x

Book Value / Share (Quarterly)$3.77

P/TBV (Annual)5.03x

Indicated Dividend (Annual)$0.03

Revenue Growth (3Y)4.57%

Cash Flow / Share (Quarterly)$0.49

Payout Ratio (TTM)7.70%

Price vs S&P 500 (YTD)-49.89%

Gross Margin (TTM)98.16%

Net Profit Margin (TTM)36.07%

EPS (TTM)$0.46

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$0.46

Revenue Growth (5Y)14.24%

EPS (Annual)$0.47

Dividend / Share (Annual)$0.03

ROI (Annual)12.34%

Gross Margin (Annual)83.18%

Net Profit Margin (5Y Avg)36.04%

Cash / Share (Quarterly)$3.48

P/E Basic Excl Extra (TTM)10.90x

Revenue Growth QoQ (YoY)-3.84%

EPS Growth (5Y)6.67%

P/E Normalized (Annual)10.90x

ROA (Last FY)11.49%

Revenue Growth TTM (YoY)-1.05%

EBITD / Share (TTM)$0.56

ROE (5Y Avg)16.04%

Operating Margin (TTM)43.11%

Cash Flow / Share (Annual)$0.49

P/B Ratio1.35x

P/B Ratio (Quarterly)1.89x

EV / Revenue (TTM)3.72x

Net Interest Coverage (TTM)21.55x

ROA (TTM)12.01%

EPS Growth QoQ (YoY)5.30%

EV / EBITDA (TTM)8.53x

EPS Incl Extra (Annual)$0.47

Current Ratio (Annual)14.81x

Quick Ratio (Quarterly)14.34x

3-Month Avg Trading Volume0.13M

52-Week Price Return-35.55%

EV / Free Cash Flow (Annual)9.92x

P/E Incl Extra (TTM)10.90x

Tangible BV / Share (Quarterly)$0.25

P/S Ratio (Annual)3.93x

Asset Turnover (Annual)0.32x

52-Week High$9.39

Operating Margin (5Y Avg)49.91%

EPS Excl Extra (Annual)$0.47

CapEx CAGR (5Y)13.40%

Tangible BV CAGR (5Y)-22.79%

26-Week Price Return-17.38%

Quick Ratio (Annual)14.34x

13-Week Price Return-26.17%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)14.81x

Enterprise Value$243.84M

Revenue / Share Growth (5Y)14.40%

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)22.05%

Inventory Turnover (Annual)2.01x

Pretax Margin (Annual)50.69%

Cash / Share (Annual)$3.48

3-Month Return Std Dev46.38%

Gross Margin (5Y Avg)90.88%

EBITDA CAGR (5Y)6.52%

EBITDA Interim CAGR (5Y)3.17%

ROE (Last FY)12.43%

Net Interest Coverage (Annual)14.08x

EPS Basic Excl Extra (Annual)$0.47

P/FCF (TTM)10.47x

Receivables Turnover (TTM)3.69x

EV / Free Cash Flow (TTM)9.92x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$0.46

Receivables Turnover (Annual)3.69x

ROI (TTM)12.94%

Dividend Growth Rate (5Y)14.78%

P/S Ratio (TTM)3.93x

Pretax Margin (5Y Avg)53.06%

Revenue / Share (Annual)$1.29

Tangible BV / Share (Annual)$0.25

Forward P/E11.49x

Free OCF CAGR (5Y)13.91%

Price vs S&P 500 (52W)-51.08%

P/E Ratio (TTM)10.90x

EPS Growth TTM (YoY)-7.04%

Year-to-Date Return-39.33%

5-Day Price Return-6.09%

EPS Normalized (Annual)$0.47

ROA (5Y Avg)14.10%

Net Profit Margin (Annual)36.07%

Month-to-Date Return-12.09%

Cash Flow / Share (TTM)$0.42

EBITD / Share (Annual)$0.56

EPS Growth (3Y)4.19%

Operating Margin (Annual)43.11%

LT Debt / Equity (Annual)0.42x

P/CF (TTM)10.01x

ROI (5Y Avg)15.95%

P/E Excl Extra (TTM)10.90x

LT Debt / Equity (Quarterly)0.42x

EPS Basic Excl Extra (TTM)$0.46

P/TBV (Quarterly)5.03x

Payout Ratio (Annual)7.39%

P/B Ratio (Annual)1.89x

Dividend / Share (TTM)$0.03

Inventory Turnover (TTM)0.22x

Pretax Margin (TTM)50.69%

Book Value / Share (Annual)$3.77

Price vs S&P 500 (13W)-28.86%

Net Margin Growth (5Y)-6.76%

Dividend Yield (TTM)0.68%

Beta0.24x

P/FCF (Annual)10.47x

Revenue / Share (TTM)$1.29

ROE (TTM)13.00%

52-Week Low$4.93

vGradeC

gGradeC

mGradeF

vgmGradeD

CUVL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.27

3.91

Industry Peers(1)

Symbol	Value Score	Growth Score	Momentum Score	P/E Ratio (Annual)	ROE (TTM)	Revenue Growth (5Y)	Indicated Dividend Yield (Annual)	Price
CUVLClinuvel Pharmaceuticals Limited American Depositary Shares	C	C	F	10.9x	13.0%	14.2%	0.3%	$5.24
CRESWCresud S.A.C.I.F. y A. Warrant	—	—	D	—	—	—	—	$0.00

About Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.